C5 inhibitor decreases the ability of human blood to kill serogroup B meningococci despite vaccination (5); investigators have described sepsis caused by nonencapsulated N. meningitidis in a patient with PNH during ravulizumab therapy (6). This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.